Showing results (631-640 of 649) with videos related to

Sort By:
Pageof 65
Hemasphere|March 18, 2025
Loss of CYLD promotes splenic marginal zone lymphomaAthanasios Pseftogas, Jessica Bordini, Silvia Heltai, et al.
Hemasphere|March 24, 2025
Low-risk MDS-A spotlight on precision medicine for SF3B1-mutated patientsShoshana Burke, Onima Chowdhury, Kevin Rouault-Pierre
Hemasphere|March 26, 2025
Mild or moderate hemophilia is not always a mild or moderate bleeding disorder: Back to the clinical phenotypeFrancesco Rodeghiero, Lisanna Ghiotto, Luca Pontalto, et al.
Hemasphere|June 5, 2024
Human leukocyte antigen (HLA) class I expression on Hodgkin-Reed-Sternberg cells is an EBV-independent major determinant of microenvironment composition in classic Hodgkin lymphomaBerit Müller-Meinhard, Nicole Seifert, Johanna Grund, et al.
Hemasphere|July 23, 2024
Correction to "Primary central nervous system lymphomas: EHA-ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up"
Hemasphere|November 27, 2025
Sequencing BCMA- and GPRC5D-targeting immunotherapies in multiple myeloma: Practical guidance from the European Myeloma NetworkNiels W C J van de Donk, Philippe Moreau, Jesus F San-Miguel, et al.
Hemasphere|December 31, 2025
TLX1 translocation variants and enhancer hijacking influence clinical outcome in T-cell acute lymphoblastic leukemiaEstelle Balducci, Thomas Steimlé, Agata Cieslak, et al.
Hemasphere|December 31, 2025
Correction to "Large B-cell lymphoma (LBCL): EHA Clinical Practice Guidelines for diagnosis, treatment, and follow-up"
Hemasphere|May 8, 2024
The evolving pattern of the monoclonal protein improves the IMWG 2/20/20 classification for patients with smoldering multiple myelomaAnna de Daniel, Luis Gerardo Rodríguez-Lobato, Natalia Tovar, et al.
Hemasphere|June 19, 2026
Phase 3 PERSPECTIVE study: Ibrutinib with rituximab for initial treatment of patients with follicular lymphomaDavid Belada, Faithlore P Gardner, Ana C de Oliveira, et al.
Pageof 65